Latest News

Merck Halts 2 Phase 3 KEYNOTE Studies of Pembrolizumab in Lung and Skin Cancers
Merck Halts 2 Phase 3 KEYNOTE Studies of Pembrolizumab in Lung and Skin Cancers

August 30th 2024

The phase 3 KEYNOTE-867 and KEYNOTE-630 studies will be stopped due to futility, following analysis from independent data monitoring committees.

Enrollment Begins in Phase 3 SOHO-02 Trial of BAY 2927088 in NSCLC
Enrollment Begins in Phase 3 SOHO-02 Trial of BAY 2927088 in NSCLC

August 29th 2024

FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC
FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC

August 27th 2024

TruSight Oncology Test Receives FDA Approval for NTRK and RET Fusion Cancers
TruSight Oncology Test Receives FDA Approval for NTRK and RET Fusion Cancers

August 27th 2024

Long-Term Immune Checkpoint Inhibition Shows Potential Extended Survival in NSCLC
Long-Term Immune Checkpoint Inhibition Shows Potential Extended Survival in NSCLC

August 21st 2024

Video Series
Video Interviews
Podcasts

More News